干白素-27可以应对慢性淋巴细胞白血病的免疫抑制
Iria Fernandez Botana1,2, Giulia Pagano1,2, Etienne Moussay1
1Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg.
Oncoimmunology
|November 8, 2023
概括
细胞因子介素-27 (IL-27) 在慢性淋巴细胞白血病 (CLL) 中显示出显著的抗瘤作用. 这种作用通过T细胞进行调解,为基于免疫的疗法提供了潜在的新途径.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 是一种流行成人白血病.
- 这种类型的CLL严重依赖于免疫微环境的相互作用.
- 这种依赖性表明了免疫治疗的潜力.
研究的目的:
- 研究细胞因子IL-27在CLL中的抗瘤作用.
- 阐明IL-27在CLL中的作用机制.
主要方法:
- 利用T细胞介导机制研究IL-27的作用.
- 在CLL的背景下评估IL-27的抗瘤活性.
主要成果:
- IL-27在CLL中显示出强大的抗瘤作用.
- 抗瘤活性取决于T细胞的参与.
结论:
- IL-27 是一种有前途的CLL治疗药物.
- T细胞介导的机制对于IL-27在CLL治疗中的有效性至关重要.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533


